Smruthi Organics Limited has scheduled a board meeting for February 13, 2026, to approve its unaudited financial results for the third quarter of fiscal year 2026. The company formally notified stock exchanges about this upcoming board meeting through an official communication dated February 5, 2026.

Board Meeting Details

The meeting has been convened in compliance with regulatory requirements and will focus on approving quarterly financial performance. The company has provided specific details about the meeting's agenda and timeline to ensure transparency with stakeholders.

Stock Exchange Notifications

Smruthi Organics Limited has formally communicated with multiple stock exchanges regarding the board meeting. The company submitted notifications to BSE Limited at P. J. Tower, Dalal Street, Mumbai, and Metropolitan Stock Exchange of India Ltd at Piramal Agastya Corporate Park, Kurla West, Mumbai. These notifications ensure compliance with listing obligations and maintain transparency with regulatory authorities.

Trading Window Restrictions

The company has implemented trading window restrictions in accordance with insider trading regulations. The trading window closure affects company insiders and designated persons who have access to unpublished price-sensitive information.

Regulatory Compliance

The board meeting announcement demonstrates Smruthi Organics Limited's adherence to SEBI regulations governing listed companies. Under Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, companies must inform stock exchanges about board meetings where financial results will be considered. This advance notice allows market participants to prepare for the upcoming financial disclosure and ensures orderly market functioning.

The company secretary and compliance officer, Urvashi D. Khanna, signed the official communication, emphasizing the formal nature of this regulatory filing. The notification maintains the company's commitment to transparent corporate governance and timely disclosure of material information to stakeholders.

Smruthi Organics Limited , a key player in the bulk drugs and drug intermediates sector, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025, showcasing a significant turnaround in its performance.

Financial Highlights

The company reported a remarkable recovery in Q2 FY2026, with a net profit of Rs 205.62 crore, a substantial improvement from the previous quarter's loss of Rs 109.54 crore. This turnaround is particularly noteworthy given the challenging market conditions.

Key financial metrics for Q2 FY2026 are as follows:

Half-Year Performance

For the half-year ended September 30, 2025, Smruthi Organics achieved:

• Total revenue of Rs 5,058.73 crore
• Net profit of Rs 96.07 crore

Segment-wise Performance

The company operates primarily in two segments:

1. API (Active Pharmaceutical Ingredients): This segment remains the major contributor, generating revenue of Rs 5,045.74 crore for the half-year.

2. Formulations: This segment reported sales of Rs 21.48 crore but incurred a loss of Rs 16.72 crore during the period.

Management Commentary

E. Purushotham, Chairman & Managing Director of Smruthi Organics Limited, stated, "The Board of Directors approved these results at a meeting held on November 11, 2025, following a limited review by our statutory auditors. We are pleased with the strong recovery in our second quarter performance, which reflects our resilience and strategic initiatives in navigating market challenges."

Balance Sheet Highlights

As of September 30, 2025:

• Total assets stood at Rs 9,963.73 crore
• Total equity was reported at Rs 7,080.85 crore
• The company maintained a cash and cash equivalents position of Rs 112.12 crore

Future Outlook

While the company has shown a robust recovery in Q2, it continues to face challenges in its formulation division. The management may need to address this segment's performance to ensure overall sustainable growth.

Investors and stakeholders should note that these are unaudited financial results, and the final audited results may differ. The company's performance in the coming quarters will be crucial in determining its growth trajectory for the fiscal year 2025-26.